Skip to main content

Table 2 Association between CILP2 expression level and clinicopathological parameters in CRC patients

From: CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in The Cancer Genome Atlas (TCGA) study

Clinicopathological parameters Expression of CILP2 mRNA in TGCA Expression of CILP2 protein in TMA cohort
High (n = 310) Low (n = 311) P value High (n = 39) Low (n = 25) P value
Age (years)    0.059    0.37
 ≤ 68 (n = 331) 177 (53.47%) 154 (46.53%)   20 (66.67%) 10 (33.33%)  
 > 68 (n = 290) 133 (45.86%) 157 (54.14%)   19 (55.88%) 15 (44.12%)  
Gender    0.400    0.8
 Male (n = 331) 160 (48.34%) 171 (51.66%)   22 (62.86%) 13 (37.14%)  
 Female (n = 290) 150 (51.72%) 140 (48.28%)   17 (58.62%) 12 (41.38%)  
Pathological T stagea    0.001    0.022
 T1/2 (n = 126) 46 (36.51%) 80 (63.49%)   13 (44.83%) 16 (55.17%)  
 T3/4 (n = 493) 263 (53.35%) 230 (46.65%)   26 (74.29%) 9 (25.71%)  
N stagea    0.005    0.2
 N0 (n = 352) 158 (44.89%) 194 (55.11%)   16 (51.61%) 15 (48.39%)  
 N1/2/3 (n = 265) 149 (56.23%) 116 (43.77%)   23 (69.70%) 10 (30.30%)  
M stagea    0.048    0.074
 M0 (n = 458) 223 (48.69%) 235 (51.31%)   30 (55.56%) 24 (44.44%)  
 M1 (n = 88) 53 (60.23%) 35 (39.77%)   9 (90.00%) 1 (10.00%)  
Clinical stagea    < 0.001    0.03
 Stage I (n = 105) 36 (34.29%) 69 (65.71%)   5 (35.71%) 9 (64.29%)  
 Stage II (n = 229) 113 (49.35%) 116 (50.65%)   8 (50.00%) 8 (50.00%)  
 Stage III (n = 179) 97 (54.19%) 82 (45.81%)   17 (70.83%) 7 (29.17%)  
 Stage IV (n = 90) 54 (60.00%) 36 (40.00%)   9 (90.00%) 1 (10.00%)  
  1. P value < 0.05 was considered statistically significant (in bold). T tumor, N regional lymph node, M metastasis
  2. aSome missing data for parameter